Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.57 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.52 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | POLA1 | P09884 | 1/20 | 0.48 |
| ▸ | POLG | P54098 | 1/20 | 0.48 |
| ▸ | FAP | Q12884 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.48 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22193336 | 0.94 | FGFR1 (0.57) | FGFR1SLC22A6ADORA2AADORA1CYP3A4 | |
| SCHEMBL21935383 | 0.82 | ADORA2A (0.54) | FGFR1SLC22A6ADORA2AADORA1CYP3A4 | |
| SCHEMBL21935275 | 0.81 | HPRT1 (0.69) | CYP3A4POLA1POLGLMNASMN1; SMN2 | |
| SCHEMBL22193338 | 0.80 | ADORA2A (0.69) | FGFR1SLC22A6ADORA2AADORA1NSD3 | |
| SCHEMBL2344093 | 0.79 | FGFR1 (0.69) | FGFR1SLC22A6ADORA2AADORA1CYP3A4 | |
| SCHEMBL7165319 | 0.78 | NSD3 (0.71) | FGFR1SLC22A6ADORA2AADORA1NSD3 | |
| SCHEMBL28797058 | 0.78 | SLC22A6 (0.67) | FGFR1SLC22A6ADORA2AADORA1CYP3A4 | |
| SCHEMBL2556627 | 0.78 | CYP3A4 (0.72) | FGFR1SLC22A6ADORA2AADORA1CYP3A4 | |
| SCHEMBL14669069 | 0.78 | CYP3A4 (0.72) | FGFR1SLC22A6ADORA2AADORA1CYP3A4 | |
| SCHEMBL2556635 | 0.78 | CYP3A4 (0.72) | FGFR1SLC22A6ADORA2AADORA1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208429-B2 | Modified nucleic acid monomer compound and oligonucleic acid analog | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-12-28 | — | — | US | disclosed |
| US-20200216488-A1 | MODIFIED NUCLEIC ACID MONOMER COMPOUND AND OLIGONUCLEIC ACID ANALOG | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216488-A1 | MODIFIED NUCLEIC ACID MONOMER COMPOUND AND OLIGONUCLEIC ACID ANALOG | POLRMT, DERA, PCNA | FGFR1 2050/4885SLC22A6 3914/4885ADORA2A 1240/4885 |
| US-11208429-B2 | Modified nucleic acid monomer compound and oligonucleic acid analog | POLRMT, DERA, PCNA | FGFR1 2050/4885SLC22A6 3914/4885ADORA2A 1240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.